Danish Pharma Company Novo Nordisk Fights to Halt Export of Russian Weight Loss Drug Copy
Novo Nordisk, the Danish pharmaceutical company producing Ozempic, is attempting to stop the export of a Russian analogue of the drug designed for weight loss. The Russian version is produced by the company Geropharm. Details of the closed legal dispute came from a letter the Novo Nordisk representative in the Russian court sent to Rospatent in November.
According to the case information, Geropharm believes that following a court decision in May, it has the right to export the drug. However, experts are divided on the legality of the export, creating uncertainty around the situation.
This dispute is significant as it may affect the pharmaceutical market and the distribution of weight control medications within Russia and internationally.
